Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Insight Molecular Diagnostics (IMDX) Equity Income (2020 - 2021)

Insight Molecular Diagnostics (IMDX) has disclosed Equity Income for 2 consecutive years, with -$270000.0 as the latest value for Q1 2021.

  • Quarterly Equity Income rose 17.93% to -$270000.0 in Q1 2021 from the year-ago period, while the trailing twelve-month figure was -$270000.0 through Dec 2021, up 82.55% year-over-year, with the annual reading at -$270000.0 for FY2021, 82.55% up from the prior year.
  • Equity Income hit -$270000.0 in Q1 2021 for Insight Molecular Diagnostics, up from -$435000.0 in the prior quarter.
  • In the past five years, Equity Income ranged from a high of -$270000.0 in Q1 2021 to a low of -$482000.0 in Q3 2020.